Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Amag Pharmaceuticals Inc (AMAG) Com Stk USD0.01

Sell:$7.84 Buy:$7.85 Change: $0.08 (1.01%)
NASDAQ:0.17%
Market closed |  Prices as at close on 26 May 2020 | Switch to live prices |
Sell:$7.84
Buy:$7.85
Change: $0.08 (1.01%)
Market closed |  Prices as at close on 26 May 2020 | Switch to live prices |
Sell:$7.84
Buy:$7.85
Change: $0.08 (1.01%)
Market closed |  Prices as at close on 26 May 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Contact details

Address:
1100 Winter St
WALTHAM
02451-1427
United States
Telephone:
+1 (617) 4983300
Website:
www.amagpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AMAG
ISIN:
US00163U1060
Market cap:
$271.78 million
Shares in issue:
34.27 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Gino Santini
    Independent Chairman of the Board
  • Scott Myers
    President, Chief Executive Officer, Director
  • Edward Myles
    Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer
  • Kelly Schick
    Chief Human Resource Officer, Senior Vice President
  • Joseph Vittiglio
    Executive Vice President, General Counsel, Corporate Secretary, Chief Business Officer
  • Anthony Casciano
    Executive Vice President and Chief Commercial Officer
  • Nancy Griffith
    Vice President - Scientific Communications And Medical Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.